Advertisement Pharmaceutical Business review - Page 621 of 5224 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 30, 2024

FDA expands approval for Shorla’s JYLAMVO for paediatric patients

The US Food and Drug Administration (FDA) has granted expanded approval to Shorla Oncology’s JYLAMVO (methotrexate) for use in paediatric indications.

JYLAMVO is an orange-flavoured liquid solution sold with a dosing syringe for administration. Credit: Shorla Oncology/Business Wire.